Biomm S.A. (BVMF:BIOM3)

Brazil flag Brazil · Delayed Price · Currency is BRL
9.39
+0.59 (6.70%)
Dec 5, 2025, 5:39 PM GMT-3
19.16%
Market Cap 1.20B
Revenue (ttm) 142.53M
Net Income (ttm) -61.66M
Shares Out 136.84M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232,800
Average Volume 128,575
Open 8.81
Previous Close 8.80
Day's Range 8.59 - 9.75
52-Week Range 6.15 - 10.73
Beta 0.92
RSI 64.91
Earnings Date Nov 14, 2025

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 130
Stock Exchange Brazil Stock Exchange
Ticker Symbol BIOM3
Full Company Profile

Financial Performance

In 2024, Biomm's revenue was 142.91 million, an increase of 20.91% compared to the previous year's 118.19 million. Losses were -77.24 million, -4.81% less than in 2023.

Financial Statements

News

There is no news available yet.